Merck, Inc.
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 245
- Registration Number
- NCT06630117
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale, California, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida, United States
🇺🇸Research Centers of America ( Hollywood ) ( Site 0004), Hollywood, Florida, United States
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06625827
- Locations
- 🇺🇸
ICON (Site 0001), Lenexa, Kansas, United States
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06625840
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International (Site 0001), Glendale, California, United States
A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06625814
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06626464
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Madison, Wisconsin, United States
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
- Conditions
- Healthy
- Interventions
- Biological: GARDASIL®9 (G9)Biological: V540B
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06623409
- Locations
- 🇺🇸
Anaheim Clinical Trials ( Site 0002), Anaheim, California, United States
🇺🇸California Clinical Trials Medical Group managed by PAREXEL ( Site 0008), Glendale, California, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida, United States
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Dana Farber Cancer Hospital ( Site 0155), Boston, Massachusetts, United States
🇺🇸Swedish Cancer Institute ( Site 0143), Seattle, Washington, United States
🇧🇪Cliniques Universitaires Saint-Luc ( Site 1203), Bruxelles, Bruxelles-Capitale, Region De, Belgium
A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
- Conditions
- HealthyNarcolepsy
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06619665
- Locations
- 🇺🇸
NeuroTrials Research Inc (Site 0001), Atlanta, Georgia, United States
🇺🇸Clinilabs (Site 0003), Eatontown, New Jersey, United States
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT06619314
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619678
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States